title: Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.
abstract: Despite the pressing need for novel cancer treatments, our improved understanding of tumor biology is not being successfully translated into better therapies. Here we present a lentiviral vector that enables in vivo validation of cancer therapeutic targets when combined with existing cancer animal models that faithfully reproduce the natural history of human disease. Unlike the conventional genetic approaches with targeted alleles, the outlined experimental strategy could be used to assess the preclinical efficacy of a growing number of putative therapeutic hits in a rapid and cost-effective manner.
authors.affiliation: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
authors.forename: Chiara
authors.initials: C
authors.lastname: Ambrogio
authors.affiliation: Sextant Therapeutics Inc, Cambridge, MA and Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Stern
authors.affiliation: Institute for Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
authors.forename: Claudio
authors.initials: C
authors.lastname: Scuoppo
authors.affiliation: Gene Bridges, GmbH Commercial Centre, Heidelberg, Germany.
authors.forename: Harald
authors.initials: H
authors.lastname: Kranz
authors.affiliation: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: Barbacid
authors.affiliation: Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Spanish National Cancer Research Center, Madrid, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Santamaría
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D004247:DNA / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D016086:Lentivirus / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D010957:Plasmids / Q000378:metabolism; D019908:Proto-Oncogene Proteins c-raf / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism; D015203:Reproducibility of Results
chemical_list: D004247:DNA; D019908:Proto-Oncogene Proteins c-raf; C495971:Hras protein, mouse; D016283:Proto-Oncogene Proteins p21(ras)
keywords: cancer mouse model; lentiviral delivery; target validation